Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

14 Nov 2024 CMB International Global Markets | Equity Research | Company Update BeiGene (BGNE US) Growing non-GAAP profit ■ Strong product sales. In 3Q24, BeiGene recorded product sales of US$993mn (+8% QoQ, +67% YoY). The 9M24 total product sales reached US$2.66bn, representing 69% of our previous FY24 estimate. In 3Q24, sales of zanubrutinib (Zanu) increased 8% QoQ or 93% Yo Y to US$690mn. The growth rate in Q3 was notably slower compared to the 30% QoQ increase in Q2, primarily due to a one- off sales or ...

Revenue Growth and Performance - Total revenue for Q3 2024 increased to $1,001.6 million, up 28.2% from $781.3 million in Q3 2023, driven by higher sales of BRUKINSA, tislelizumab, and in-licensed products from Amgen[119][120] - Product revenue for Q3 2024 reached $993.4 million, a 66.9% increase from $595.3 million in Q3 2023[119] - Total revenue increased by 28.2% to $1,001.6 million in Q3 2024 compared to $781.3 million in Q3 2023, driven by a 66.9% increase in product revenue to $993.4 million[121][122] - Total revenue for the nine months ended September 30, 2024 increased 47.0% to $2,682.4 million compared to the same period in 2023[138] - Total revenue increased by 47.0% to $2,682.4 million for the nine months ended September 30, 2024, compared to $1,824.4 million in the prior-year period[139] BRUKINSA Performance - BRUKINSA global revenue for Q3 2024 was $690 million, solidifying its leadership in chronic lymphocytic leukemia (CLL) treatment[113] - BRUKINSA global revenue grew 93.0% to $690.3 million in Q3 2024, with U.S. revenue up 86.5% to $503.7 million and Europe revenue surging 217.2% to $97.3 million[123] - BRUKINSA global revenue increased by 107.0% to $1,816.2 million, with U.S. revenue growing by 111.0% to $1,334.6 million and Europe revenue growing by 221.0% to $245.5 million[141] Tislelizumab Performance - Tislelizumab revenue in China increased 12.8% to $162.9 million in Q3 2024, with additional indications eligible for 2025 NRDL inclusion[124] - Tislelizumab revenue in China increased by 14.1% to $466.4 million, driven by broader reimbursement and expanded salesforce[142] Amgen Products Performance - Amgen products revenue in China more than doubled, increasing 101.5% to $101.6 million in Q3 2024, primarily due to XGEVA sales growth[125] - XGEVA revenue grew 159.4% to $63.4 million in Q3 2024, contributing to the strong performance of Amgen products in China[122] - Amgen products revenue in China increased to $263.6 million, primarily due to increased XGEVA demand following NRDL inclusion[143] Collaboration Revenue - Collaboration revenue for Q3 2024 decreased by 95.6% to $8.2 million from $186.0 million in Q3 2023 due to the termination of Novartis collaborations[119][120] - Collaboration revenue decreased 95.6% to $8.2 million in Q3 2024, primarily from Novartis marketing agreement, compared to $186.0 million in Q3 2023[126] - Collaboration revenue decreased by 92.1% to $20.9 million, primarily related to the Novartis broad markets marketing agreement[144] Gross Margin - Gross margin increased to $823.0 million in Q3 2024, with adjusted gross margin percentage rising to 84.9% from 84.4% in Q3 2023, driven by higher BRUKINSA sales mix[127] - Gross margin on product sales increased to 83.7% (GAAP) and 84.8% (adjusted) for the nine months ended September 30, 2024, up from 82.4% and 83.0% respectively in the prior-year period[145] Research and Development Expenses - Research and development expenses for Q3 2024 increased by 9.5% to $496.2 million from $453.3 million in Q3 2023[119] - Research and development expenses increased 9.5% to $496.2 million in Q3 2024, with external R&D expenses up 8.9% to $171.0 million and internal R&D expenses up 9.8% to $325.1 million[129][131] - Research and development expense increased by 9.9% to $1,411.3 million, with external R&D expenses rising by 14.3% to $501.2 million[146] - Adjusted R&D expenses for Q3 2024 were $405.5 million, compared to $396.1 million in Q3 2023[156] Selling, General, and Administrative Expenses - Selling, general, and administrative expenses for Q3 2024 rose by 24.5% to $455.2 million from $365.7 million in Q3 2023[119] - Selling, general and administrative expenses increased 24.5% to $455.2 million in Q3 2024, primarily due to commercial expansion for BRUKINSA in the U.S. and Europe[132][134] - Selling, general and administrative expenses increased by 21.7% to $1,326.4 million, primarily due to commercial expansion for BRUKINSA in the U.S. and Europe[151] - Adjusted operating expenses for Q3 2024 were $786.3 million, compared to $704.6 million in Q3 2023[156] Pipeline and Regulatory Updates - The company expanded its oncology pipeline with four new molecular entities (NMEs) entering clinical trials in Q3 2024, bringing the year-to-date total to eight[113] - TEVIMBRA received positive opinions from the European Medicines Agency for extended authorization in gastric and esophageal cancers[114] - The FDA granted Fast Track Designation to BGB-16673 for relapsed or refractory CLL or small lymphocytic lymphoma[116] Financial Position and Cash Flow - The company achieved $1 billion in quarterly total revenue for Q3 2024, marking its second consecutive quarter of positive non-GAAP operating income[113] - Adjusted income from operations in Q3 2024 was $65.6 million, compared to a loss of $16.3 million in Q3 2023[156] - Cash, cash equivalents, and restricted cash as of September 30, 2024, were $2.7 billion, down from $3.2 billion as of December 31, 2023[157] - Net cash used in operating activities improved by $720.0 million in the nine months ended September 30, 2024, compared to the prior year period[162] - Net cash used in investing activities was $454.7 million in the nine months ended September 30, 2024, compared to $122.6 million provided in the prior year period[163] - Net cash provided by financing activities was $198.0 million in the nine months ended September 30, 2024, compared to $69.4 million in the prior year period[164] - The company expects to repay approximately $863.8 million of loans in the next 12 months and plans to refinance them[165] - The company had $0.8 billion in cash remaining from the STAR Offering proceeds as of September 30, 2024[160] Contractual Obligations and Commitments - Total contractual obligations amount to $1.755 billion, with $1.125 billion due in the short term and $630.8 million in the long term[173] - Operating lease commitments total $55.4 million, with $4.6 million due in the short term and $50.8 million in the long term[173][174] - Non-cancellable purchase commitments amount to $155.9 million, with $125.9 million related to inventory from Amgen[175] - Total debt obligations due in the next twelve months are $863.8 million, with long-term debt obligations at $187.5 million[176] - Remaining co-development funding commitment under the Amgen collaboration is $379.1 million[179] - Capital commitments for property, plant, and equipment acquisition total $66.2 million[181] Interest and Currency Impact - Interest income, net decreased by 30.7% to $40.0 million due to lower interest rates on cash and cash equivalents[152] - A 100-basis point increase in interest rates would increase annual pre-tax interest expense by $7.4 million[185] - RMB appreciated approximately 1.1% against the U.S. dollar in the nine months ended September 30, 2024[187] - Inflation has not had a material effect on the company's results of operations during the nine months ended September 30, 2024[190] Tax and Cost of Sales - Income tax expense increased to $45.3 million, primarily due to U.S., Switzerland, and China tax expenses[154] - Adjusted cost of sales for products in Q3 2024 was $149.7 million, compared to $93.0 million in Q3 2023[156]

Exhibit 99.1 BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates • Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and second consecutive quarter of positive non-GAAP operating income • Strengthened franchise leadership in chronic lymphocytic leukemia (CLL) with foundational therapy BRUKINSA, global revenue of $690 million, rapidly progressing pivotal programs for late-stage hematology pipeline • Expanded oncology pipeline with four new mol ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the performance of the company’s marketed portfolio of drugs. Beigene currently has three approved medicines – Brukinsa (various blood cancers), Tevimbra (various sol ...

Exhibit 99.1 BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates • Generated total revenues of $929 million, an increase of 56% from the prior-year period; reduced GAAP operating loss and achieved non-GAAP operating income • Strengthened hematology leadership with global BRUKINSA revenues of $637 million, an increase of 107% from the prioryear period; advanced pivotal programs for BCL2 inhibitor sonrotoclax and BTK-targeted degrader BGB ...

Shares of BeiGene, Ltd. (BGNE) have gained 28.8% over the past four weeks to close the last trading session at $202.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $258.45 indicates a potential upside of 27.8%.The mean estimate comprises 11 short-term price targets with a standard deviation of $55.54. While the lowest estimate of $152 indicates a 24.8% decline from the curre ...

BeiGene, Ltd. (BGNE) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BGNE's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typic ...

Shares of BeiGene, Ltd. (BGNE) have gained 20.1% over the past four weeks to close the last trading session at $182.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $257.41 indicates a potential upside of 40.9%.The mean estimate comprises 11 short-term price targets with a standard deviation of $56.75. While the lowest estimate of $161 indicates a 11.9% decline from the curre ...